We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -5.80% | 3.25 | 3.20 | 3.30 | 3.45 | 3.25 | 3.45 | 495,968 | 12:19:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -2.37M | -0.0262 | -1.24 | 2.93M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/9/2020 08:02 | Managed to bag another 30k at 64.75p on open and expecting £1 today | tburns | |
28/9/2020 08:01 | Well I got that wrong !!I thought 80p okie lol | nico115 | |
28/9/2020 07:56 | Yeah, you're right mally. - I'm gonna sell the lot in five minutes, and put the lot into BT. - or the 3:45 at Newton Abbot. | 801710245 | |
28/9/2020 07:56 | NOTE Physiomics earlier this year signed a deal with the No.1 Prostate Cancer drug seller Astellas (Xtandi (enzalutamide) which sells $3bn p.a.) Could they be a bridge for VAL to approach Astellas with regard to partnering VAL201 with Xtandi ? | the stigologist | |
28/9/2020 07:54 | Not sure these results are so good long way to go for drug to come to market | mally6 | |
28/9/2020 07:54 | Gotta be a rerate for 100 Market Cap | shares188 | |
28/9/2020 07:50 | everyone had an early heads-up with the "it bloody works" | jusjusjus | |
28/9/2020 07:50 | Suzy Dilly tweeting about the safety details and how they are helpful for the VAL drug pipeline...mentionin BC201 could be absolutely HUGE | fez | |
28/9/2020 07:49 | remember SNG went from 35p to 190p (open/close) on that day, then went to 249p (close) 4 weeks later | jusjusjus | |
28/9/2020 07:48 | Just goes to show the MM tactics of Friday, when the share price was driven 'sub-50p'. I had a feeling this would happen at some point at the start of Friday trading - but I'd have been lambasted if I'd suggested that at the time. Who thinks the MMs may have had an early 'heads-up' - or am I being too much 'the conspiracy theorist'? | 801710245 | |
28/9/2020 07:46 | If dddd can do it so can val. mcap is extremely low | justtrying1 | |
28/9/2020 07:44 | Not sure those results could have been better . Let us see where this goes in the first hour. But do not sell early guys. We will see wave 2 and 3 IMHO as the day develops and news is broadcast | stoneme | |
28/9/2020 07:43 | I would be shocked if that low Look at dddd and SNG on data that didn't look as good as ours | nico115 | |
28/9/2020 07:41 | Excellent results guys | justtrying1 | |
28/9/2020 07:38 | Get in, what a great start to the week GLA | tburns | |
28/9/2020 07:34 | First price 65:75... | nobbygnome | |
28/9/2020 07:34 | Happy days guys. Great results. Huge blue day ahead. ? | dovey21 | |
28/9/2020 07:32 | And still only a MC of 30 million ... | bigman786 | |
28/9/2020 07:30 | What a future Val have now. | 412069 | |
28/9/2020 07:26 | Wow now that's great data Excellent news for both patients and shareholders As George said "it bloody works "!! | nico115 | |
28/9/2020 07:24 | Great result for prostate cancer sufferers - potentially all men! - 54% is excellent. DDDD had a similar disease control rate of 42% with their recent MRx0518 / KEYTRUDA trial and the share price has virtually doubled. | fez | |
28/9/2020 07:22 | Triple Whammy good news for PYC from VAL news 1. ORR of 50% is very good early result. Shows promise to get VAL201 licensed to a bigger player. Physiomics get FREE CARRIED UPSIDE and share of ANY licensing income (including upfronts, milestones, royalties) 2. Note VAL comment on 'optimal dosing strategies'. Given PYC helped them develop drug in first place Physiomics should get follow on work now to develop these 'optimal dosing strategies' given Physiomics are experts in Modelling and Simulation of exactly that 3. In considering Partnering Physiomics modelling expertise can also be used to model which drug will work best in combination with VAL201 and this can be used to narrow search for best partner. | the stigologist |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions